Drug profile · INN
remimazolam besylate
BYFAVO
remimazolam besylate (BYFAVO) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — remimazolam besylate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
remimazolam besylate (BYFAVO) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is remimazolam besylate?
remimazolam besylate (BYFAVO) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for remimazolam besylate?
BYFAVO is a marketed brand name for remimazolam besylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of remimazolam besylate?
remimazolam besylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.